

Precision Medicine in Solid Tumors November 15 - 17, 2018 | Seoul, South Korea





Curriculum Vitae

Personal Information * CV must be written in English		
Title	Chief	
Name	Toshikazu Ushijima	
Country	Japan	
Affiliation	National Cancer Center Research Institute	N SHOW
E-mail	tushijim@ncc.go.jp	

Curriculum Vitae * CV must be written in English

Dr. Toshikazu Ushijima is the Chief of Division of Epigenomics, National Cancer Center Research Institute (NCCRI), Tokyo. He graduated from the University of Tokyo School of Medicine in 1986, and spent three years in clinical training mainly in hematology. He started basic research in 1989 at the National Cancer Center Research Institute, and was promoted to a Chief of Carcinogenesis Division in 1997. The Division was re-named as Division of Epigenomics in 2010. He also served as a Deputy Director of the Research Institute from 2011 to 2014.

He developed one of the first genome-wide screening techniques for changes in DNA methylation. He isolated a novel tumor-suppressor gene in gastric cancer, established the concept of epigenetic field cancerization, and demonstrated that the degree of a field can be used for accurate cancer risk diagnosis. He also showed that inflammation triggered by *Helicobacter pylori* infection is critical for induction of aberrant DNA methylation, and revealed the molecular mechanism underlying the induction. He brought the finding of epigenetic field cancerization to precision cancer risk diagnosis by conducting a multicenter prospective cohort study.

He is currently serving as an editor for Cancer Letters, Gastric Cancer, and Cancer Science, and as an editorial board member for many journals. He also served as a Senior Editor for Cancer Research from 2010 to 2017. He has received Incitement (1997) and Mauvernay (2009) awards of JCA, President award of NCC (2012), the Tahara award of the Japanese Gastroenterological Carcinogenesis Society (2012), and the Uehara *Helicobacter* award of the Japanese *Helicobacter* Society (2013).

He is a board member for the Japanese Cancer Association (2018-), served as the president for the Japanese Society for Epigenetics (2013-2016), and worked as a member for multiple AACR committees.